Fidelity Investments’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $188K | Buy |
3,477
+72
| +2% | +$4.01K | ﹤0.01% | 3516 |
|
|
2025
Q4 | $191K | Buy |
3,405
+588
| +21% | +$30.5K | ﹤0.01% | 3465 |
|
|
2025
Q3 | $135K | Sell |
2,817
-406
| -13% | -$18.2K | ﹤0.01% | 3538 |
|
|
2025
Q2 | $131K | Sell |
3,223
-657
| -17% | -$26.4K | ﹤0.01% | 3486 |
|
|
2025
Q1 | $170K | Hold |
3,880
| – | – | ﹤0.01% | 3314 |
|
|
2024
Q4 | $167K | Buy |
3,880
+107
| +3% | +$4.87K | ﹤0.01% | 3342 |
|
|
2024
Q3 | $167K | Hold |
3,773
| – | – | ﹤0.01% | 3258 |
|
|
2024
Q2 | $150K | Buy |
3,773
+13
| +0.3% | +$527 | ﹤0.01% | 3146 |
|
|
2024
Q1 | $162K | Buy |
3,760
+56
| +2% | +$2.41K | ﹤0.01% | 3102 |
|
|
2023
Q4 | $154K | Buy |
3,704
+659
| +22% | +$25K | ﹤0.01% | 3040 |
|
|
2023
Q3 | $121K | Sell |
3,045
-4
| -0.1% | -$169 | ﹤0.01% | 3040 |
|
|
2023
Q2 | $125K | Sell |
3,049
-32
| -1% | -$1.32K | ﹤0.01% | 3087 |
|
|
2023
Q1 | $126K | Buy |
3,081
+119
| +4% | +$5K | ﹤0.01% | 3126 |
|
|
2022
Q4 | $121K | Sell |
2,962
-371
| -11% | -$15.4K | ﹤0.01% | 3141 |
|
|
2022
Q3 | $134K | Buy |
3,333
+2,874
| +626% | +$123K | ﹤0.01% | 3180 |
|
|
2022
Q2 | $19K | Buy |
459
+176
| +62% | +$7.38K | ﹤0.01% | 3904 |
|
|
2022
Q1 | $13K | Hold |
283
| – | – | ﹤0.01% | 4175 |
|
|
2021
Q4 | $13K | Buy |
283
+1
| +0.4% | +$47 | ﹤0.01% | 3585 |
|
|
2021
Q3 | $13K | Sell |
282
-1
| -0.4% | -$50 | ﹤0.01% | 3555 |
|
|
2021
Q2 | $15K | Sell |
283
-108
| -28% | -$5.42K | ﹤0.01% | 3466 |
|
|
2021
Q1 | $20K | Buy |
391
+108
| +38% | +$5.76K | ﹤0.01% | 3251 |
|
|
2020
Q4 | $15K | Sell |
283
-159
| -36% | -$7.6K | ﹤0.01% | 3239 |
|
|
2020
Q3 | $19K | Buy |
442
+251
| +131% | +$11K | ﹤0.01% | 3067 |
|
|
2020
Q2 | $8K | Sell |
191
-226
| -54% | -$9.34K | ﹤0.01% | 3170 |
|
|
2020
Q1 | $15K | Sell |
417
-660
| -61% | -$28.1K | ﹤0.01% | 3023 |
|
|
2019
Q4 | $49K | Buy |
1,077
+895
| +492% | +$35.5K | ﹤0.01% | 2900 |
|
|
2019
Q3 | $6K | Sell |
182
-134
| -42% | -$4.98K | ﹤0.01% | 3374 |
|
|
2019
Q2 | $13K | Buy |
316
+1
| +0.3% | +$39 | ﹤0.01% | 3184 |
|
|
2019
Q1 | $13K | Sell |
315
-533
| -63% | -$21.7K | ﹤0.01% | 3077 |
|
|
2018
Q4 | $31K | Sell |
848
-214
| -20% | -$9.13K | ﹤0.01% | 2819 |
|
|
2018
Q3 | $52K | Buy |
+1,062
| New | +$50.3K | ﹤0.01% | 2825 |
|
|
2015
Q4 | – | Sell |
-4,265
| Closed | -$200K | – | 2781 |
|
|
2015
Q3 | $200K | Buy |
4,265
+153
| +4% | +$9.22K | ﹤0.01% | 2684 |
|
|
2015
Q2 | $251K | Buy |
4,112
+838
| +26% | +$52.2K | ﹤0.01% | 2680 |
|
|
2015
Q1 | $205K | Buy |
+3,274
| New | +$194K | ﹤0.01% | 2717 |
|
|
2014
Q3 | – | Sell |
-662,176
| Closed | -$34.4M | – | 2834 |
|
|
2014
Q2 | $34.4M | Buy |
662,176
+240,460
| +57% | +$11.6M | ﹤0.01% | 1530 |
|
|
2014
Q1 | $19.8M | Sell |
421,716
-858,600
| -67% | -$40.6M | ﹤0.01% | 1758 |
|
|
2013
Q4 | $56.3M | Buy |
+1,280,316
| New | +$53.3M | 0.01% | 1256 |
|
|
2013
Q3 | – | Sell |
-1,192,934
| Closed | -$42M | – | 2682 |
|
|
2013
Q2 | $42M | Buy |
+1,192,934
| New | +$40.3M | 0.01% | 1329 |
|
Other funds holding XPH
KWM
FCBT
Fidelity Investments's XPH Position: Q1 2026 in Review
Fidelity Investments increased its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 2.1% in Q1 2026, buying an estimated $4.01K and bringing the position to 3,477 shares worth $188K. The position accounts for ﹤0.01% of the portfolio, ranked #3516.
Fidelity Investments first reported a position in XPH in Q2 2013 and has held it in 38 quarters since. The position peaked at $56.3M in Q4 2013. 82 funds tracked by Wall St. Rank hold XPH as of Q1 2026.
- Fidelity Investments held 3,477 shares of State Street SPDR S&P Pharmaceuticals ETF worth $188K as of Q1 2026.
- Fidelity Investments bought 72 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2026, an estimated $4.01K.
- State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #3516 holding.
- Fidelity Investments first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2013 and has held it in 38 quarters since.
- Fidelity Investments's State Street SPDR S&P Pharmaceuticals ETF position peaked at $56.3M in Q4 2013.
- 82 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.